<DOC>
	<DOCNO>NCT00142415</DOCNO>
	<brief_summary>This Phase I/II , single-center , dose-escalation study . 177-Lutetium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-cG250 ( 177-Lu-DOTA-cG250 ) administer start dose 30 mCi/m^2 177-Lu ( fix dose 10 mg cG250 ) escalate increment 10 mCi/m^2 177-Lu sequentially enrol cohort accord standard 3 + 3 design determination maximum tolerate dose ( MTD ) . The primary objective determine safety , target , dosimetry 177-Lu-DOTA-cG250 subject advance renal cell carcinoma . The secondary objective measurement tumor response accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.0 .</brief_summary>
	<brief_title>Phase I/II Dose-escalation Study Lutetium-177-labeled cG250 Patients With Advanced Renal Cancer</brief_title>
	<detailed_description>Prior administration 177-Lu-DOTA-cG250 , subject receive 5 mCi/10 mg 111-Indium-DOTA-cG250 ( 111-In-DOTA-cG250 ) antibody ( image dose ) . Whole body blood measurement radioactivity obtain least 3 occasion 1 week determine target dosimetry . If least one know evaluable metastatic lesion visualize 111-In-DOTA-cG250 , single dose therapeutic 177-Lu-DOTA-cG250 administer follow week . In absence disease progression recovery toxicity , subject may retreat sooner 12 week previous treatment dose 75 % previous dose , total 3 treatment . Only subject normal pharmacokinetics diagnostic 111-In-DOTA-cG250 study ( indicative human anti-chimeric antibody [ HACA ] negativity ) eligible re-treatment . Subjects initial cohort enrol sequentially receive 30 mCi/m^2 177-Lu-DOTA-cG250 ( fix dose 10 mg cG250 ) . In absence dose-limiting toxicity , dose escalated subsequent cohort 10 mCi/m^2 increment 177-Lu . At least 3 subject per dose level follow 12 week image , biochemical , hematologic test . Safety monitor continuously throughout study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects proven advance progressive renal cell carcinoma ( RCC ) clear cell type . 2 . At least one evaluable lesion &lt; 5 cm . 3 . Karnofsky performance status ≥ 70 % . 4 . Laboratory value obtain &lt; 14 day prior registration : White blood cell ( WBC ) ≥ 3.5 × 10^9/L Platelet count ≥ 100 × 10^9/L Hemoglobin ≥ 6 mmol/L Total bilirubin ≤ 2 × upper limit normal ( ULN ) Aspartate aminotransferase alanine aminotransferase ≤ 3 × ULN ( &lt; 5 × ULN liver metastasis present ) Serum creatinine ≤ 2 × ULN 5 . Negative pregnancy test woman childbearing potential ( urine serum ) . 6 . Age 18 year . 7 . Ability provide write informed consent . 1 . Known metastasis brain . 2 . Untreated hypercalcemia . 3 . Metastatic disease limit bone . 4 . Preexposure murine/chimeric antibody therapy . 5 . Chemotherapy , external beam radiation immunotherapy within 4 week prior study . Limited field external beam radiotherapy prevent pathological fracture allow , unirradiated , evaluable lesion present elsewhere . 6 . Cardiac disease New York Heart Association classification III IV . 7 . Subjects pregnant , nursing reproductive potential practice effective method contraception . 8 . Any unrelated illness , e.g. , active infection , inflammation , medical condition laboratory abnormality , judgement investigator would significantly affect subject 's clinical status . 9 . Life expectancy &lt; 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced Renal Cell Carcinoma</keyword>
	<keyword>Clear Cell Renal Cell Carcinoma ( CCRCC )</keyword>
	<keyword>Lutetium-177</keyword>
	<keyword>177-Lu</keyword>
	<keyword>cG250</keyword>
	<keyword>DOTA-cG250</keyword>
	<keyword>Monoclonal Antibody</keyword>
</DOC>